Antengene (HKG:6996) obtained new drug application approval for three indications of XPOVIO (selinexor) from the Indonesia National Agency of Drug and Food Control, a Wednesday Hong Kong bourse filing said.
The indications include a combination with bortezomib and dexamethasone used for the treatment of multiple myeloma in adult patients, a combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma, and as a monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma in adult patients.
Multiple myeloma is a cancer related to the white blood cells called plasma cells, while diffuse large B-cell lymphoma is cancer related to the white blood cells called lymphocytes.
Shares of the company were up nearly 11% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。